Skip to main content

Table 3 Distribution of CYP2C19 polymorphisms in MACE, no-MACE, bleeding, and no-bleeding patients

From: Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study

Variables Overall (n = 351) MACE
(n = 101)
No-MACE (n = 250) P value Bleeding
(n = 18)
No-bleeding
(n = 333)
P value
Polymorphisms, n (%)
CYP2C19*2        
 GG 251 (71.5) 58 (57.4) 193 (77.2) 0.001* 16 (88.9) 235 (70.6) 0.273
 GA 90 (25.6) 38 (37.6) 52 (20.8) 2 (11.1) 88 (26.4)
 AA 10 (2.9) 5 (5.0) 5 (2.0) / 10 (3.0)
 A allele 110 (15.7) 48 (23.8) 62 (12.4)  < 0.001* 2 (5.6) 108 (16.2) 0.139
 G allele 692 (84.3) 154 (76.2) 438 (87.6) 34 (94.4) 558 (83.8)
CYP2C19*3        
 GG 328 (93.4) 91 (90.1) 237 (94.8) 0.107 16 (88.9) 312 (93.7) 0.333
 GA 23 (6.6) 10 (9.9) 13 (5.2) 2 (11.1) 21 (6.3)
 AA / / / / /  
 A allele 23 (3.3) 10 (5.0) 13 (2.6) 0.113 2 (5.6) 21 (3.2) 0.332
 G allele 679 (96.7) 192 (95.0) 487 (97.4) 34 (94.4) 645 (96.8)
CYP2C19*17        
 CC 252 (71.8) 81 (80.2) 171 (68.4) 0.08 10 (55.6) 242 (72.7) 0.139
 CT 91 (25.9) 18 (17.8) 73 (29.2) 7 (38.9) 84 (25.2)
 TT 8 (2.3) 2 (2.0) 6 (2.4) 1 (5.6) 7 (2.1)
 T allele 107 (15.2) 22 (10.9) 85 (17.0) 0.041* 9 (25.0) 98 (14.7) 0.094
 C allele 595 (84.8) 180 (89.1) 415 (83.0) 27 (75.0) 568 (85.3)
Metabolizer Phenotype, n (%)
 EMs 147 (41.9) 37 (36.6) 110 (41.6) 0.205 7 (38.9) 140 (42.0) 0.792
 IMs 107 (30.5) 43 (42.6) 64 (25.6) 0.002* 4 (22.2) 103 (30.9) 0.601
 PMs 12 (3.4) 7 (6.9) 5 (2.0) 0.021* / 12 (3.6) 1.0
 UMs 85 (24.2) 14 (13.9) 71 (28.4) 0.004* 7 (38.9) 78 (23.4) 0.158
  1. MACE major adverse cardiac events, EMs extensive metabolizers, IMs intermediate metabolizers, PMs poor metabolizers, UMs ultra-metabolizers; *P < 0.05,* the difference of MACE vs. no-MACE by χ2 test at 0.05